KR920006349B1 - 미생물을 이용한 α- 및 β-인터페론의 제조방법 - Google Patents

미생물을 이용한 α- 및 β-인터페론의 제조방법 Download PDF

Info

Publication number
KR920006349B1
KR920006349B1 KR1019830002362A KR830002362A KR920006349B1 KR 920006349 B1 KR920006349 B1 KR 920006349B1 KR 1019830002362 A KR1019830002362 A KR 1019830002362A KR 830002362 A KR830002362 A KR 830002362A KR 920006349 B1 KR920006349 B1 KR 920006349B1
Authority
KR
South Korea
Prior art keywords
ifn
interferon
dna
colon
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
KR1019830002362A
Other languages
English (en)
Korean (ko)
Other versions
KR840004944A (ko
Inventor
드브르킨-라슬 에바
드보르킨 마크-브루스
퀸터 아돌프 마크.
마인들 페터
보도 게르하르트
스베틀리 페터
Original Assignee
닥터칼 토매 게젤샤프트 미트 베슈랭크터 하프퉁
요하네스 케크 · 프리쯔 좀머
프리쯔 좀머
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6164725&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR920006349(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 닥터칼 토매 게젤샤프트 미트 베슈랭크터 하프퉁, 요하네스 케크 · 프리쯔 좀머, 프리쯔 좀머 filed Critical 닥터칼 토매 게젤샤프트 미트 베슈랭크터 하프퉁
Publication of KR840004944A publication Critical patent/KR840004944A/ko
Application granted granted Critical
Publication of KR920006349B1 publication Critical patent/KR920006349B1/ko
Expired legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1019830002362A 1982-05-28 1983-05-28 미생물을 이용한 α- 및 β-인터페론의 제조방법 Expired KR920006349B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19823220116 DE3220116A1 (de) 1982-05-28 1982-05-28 Mikrobiologisch hergestellte (alpha)- und ss-interferone, dna-sequenzen, die fuer diese interferone codieren, mikroorganismen, die diese genetische information enthalten, und verfahren zu ihrer herstellung
DE3220116.8 1982-05-28
DEP3220116.8 1982-05-28

Publications (2)

Publication Number Publication Date
KR840004944A KR840004944A (ko) 1984-10-31
KR920006349B1 true KR920006349B1 (ko) 1992-08-03

Family

ID=6164725

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019830002362A Expired KR920006349B1 (ko) 1982-05-28 1983-05-28 미생물을 이용한 α- 및 β-인터페론의 제조방법

Country Status (22)

Country Link
US (1) US4820638A (enrdf_load_stackoverflow)
EP (1) EP0095702B1 (enrdf_load_stackoverflow)
JP (2) JPH0774238B2 (enrdf_load_stackoverflow)
KR (1) KR920006349B1 (enrdf_load_stackoverflow)
AT (1) ATE42114T1 (enrdf_load_stackoverflow)
AU (1) AU565479B2 (enrdf_load_stackoverflow)
DD (1) DD211359C4 (enrdf_load_stackoverflow)
DE (2) DE3220116A1 (enrdf_load_stackoverflow)
DK (1) DK164742C (enrdf_load_stackoverflow)
ES (2) ES8403522A1 (enrdf_load_stackoverflow)
FI (1) FI82072C (enrdf_load_stackoverflow)
GR (1) GR79236B (enrdf_load_stackoverflow)
HK (1) HK112893A (enrdf_load_stackoverflow)
HU (1) HU196452B (enrdf_load_stackoverflow)
IL (1) IL68790A (enrdf_load_stackoverflow)
MX (1) MX9202815A (enrdf_load_stackoverflow)
NO (1) NO168538C (enrdf_load_stackoverflow)
NZ (1) NZ204384A (enrdf_load_stackoverflow)
SG (1) SG38692G (enrdf_load_stackoverflow)
SU (1) SU1346048A3 (enrdf_load_stackoverflow)
UA (1) UA8037A1 (enrdf_load_stackoverflow)
ZA (1) ZA833845B (enrdf_load_stackoverflow)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3247922A1 (de) * 1982-12-24 1984-06-28 Boehringer Ingelheim International GmbH, 6507 Ingelheim Dna-sequenzen, deren herstellung, diese sequenzen enthaltende plasmide und deren verwendung zur synthese eukaryotischer genprodukte in prokaryoten
DE3515336C2 (de) * 1985-04-27 1994-01-20 Boehringer Ingelheim Int Verfahren zur Herstellung und Reinigung von â-Interferon
US4709324A (en) * 1985-11-27 1987-11-24 Motorola, Inc. Data processor control unit having an interrupt service using instruction prefetch redirection
CA2025180A1 (en) * 1989-10-12 1991-04-13 William G. Weisburg Nucleic acid probes and methods for detecting pathogenic candida yeasts
US6685933B1 (en) * 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
WO2002036072A2 (en) * 2000-11-03 2002-05-10 Biomedicines, Inc. Method for short-term and long-term drug dosimetry
FR2817559B1 (fr) * 2000-12-06 2003-12-12 Genodyssee Procede de determination d'un ou plusieurs polymorphisme(s) fontionnel(s) dans la sequence nucleique d'un gene "candidat" fonctionnel preselectionne et ses applications
FR2821625B1 (fr) * 2001-03-01 2003-05-16 Genodyssee Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
FR2823220B1 (fr) * 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
WO2003063573A2 (en) * 2001-11-09 2003-08-07 Intarcia Therapeutics, Inc. Method for treating diseases with omega interferon
US20040063912A1 (en) * 2002-03-15 2004-04-01 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
ES2343518T3 (es) * 2002-09-09 2010-08-03 Hanall Biopharma Co., Ltd. Polipeptidos interferon alfa modificados resistentes a proteasas.
KR20060130182A (ko) * 2004-02-02 2006-12-18 암브룩스, 인코포레이티드 변형된 인간 인터페론 폴리펩티드 및 이의 용도
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
CA2651855C (en) 2006-05-30 2011-08-02 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
PT2359808E (pt) 2006-08-09 2013-08-28 Intarcia Therapeutics Inc Sistemas de entrega osmótica e montagens de pistão
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
IL290847B2 (en) 2007-04-23 2024-11-01 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
DK2462246T3 (da) 2009-09-28 2017-11-06 Intarcia Therapeutics Inc Hurtig etablering og/eller afslutning af væsentlig steady-state-lægemiddelafgivelse
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
WO2014033266A1 (en) 2012-08-31 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MA44390A (fr) 2015-06-03 2019-01-23 Intarcia Therapeutics Inc Systèmes de mise en place et de retrait d'implant
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CA3049034A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2906160A1 (de) * 1979-02-17 1980-09-04 Thomae Gmbh Dr K Verbessertes verfahren zur herstellung von humaninterferon
AU538665B2 (en) * 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna
IL58765A (en) * 1979-11-21 1986-09-30 Yeda Res & Dev Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta
US4530901A (en) * 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
DE3165463D1 (en) * 1980-01-08 1984-09-20 Biogen Nv Dna sequences, recombinant dna molecules and processes for producing human interferon-alpha like polypeptides
GB2068970B (en) * 1980-02-06 1983-06-22 Searle & Co Recombinant dna technique for the preparation of a protein resembling human interferon
DE3005897A1 (de) * 1980-02-16 1981-09-03 Hoechst Ag, 6000 Frankfurt Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus
DE3005843A1 (de) * 1980-02-16 1981-09-10 Hoechst Ag, 6000 Frankfurt Genprodukt eines hoeheren organismus aus einem dieses gen enthaltenden mikroorganismus
ES506955A0 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
DE3106982A1 (de) * 1981-02-25 1982-09-09 Dr. Karl Thomae Gmbh, 7950 Biberach "neues tridecadeoxynukleotid, verfahren zu seiner herstellung und verwendung"
IL63327A (en) * 1981-07-16 1985-11-29 Yeda Res & Dev Production of interferon beta1 and alpha-phage recombinants for its production in host bacteria
GB2108510B (en) 1981-10-03 1984-12-12 Ciba Geigy Ag Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof

Also Published As

Publication number Publication date
NO168538B (no) 1991-11-25
KR840004944A (ko) 1984-10-31
DE3220116C2 (enrdf_load_stackoverflow) 1993-02-18
DK164742B (da) 1992-08-10
DK239383D0 (da) 1983-05-27
FI831818L (fi) 1983-11-29
IL68790A0 (en) 1983-09-30
ES8500321A1 (es) 1984-10-01
SU1346048A3 (ru) 1987-10-15
ATE42114T1 (de) 1989-04-15
EP0095702A1 (de) 1983-12-07
JPH0678774A (ja) 1994-03-22
IL68790A (en) 1991-06-10
JP2558422B2 (ja) 1996-11-27
EP0095702B1 (de) 1989-04-12
AU1504483A (en) 1983-12-01
DE3379591D1 (en) 1989-05-18
FI82072C (fi) 1991-01-10
DK239383A (da) 1983-11-29
NZ204384A (en) 1986-11-12
NO168538C (no) 1992-03-04
DK164742C (da) 1992-12-28
ZA833845B (en) 1985-01-30
ES522762A0 (es) 1984-03-16
HK112893A (en) 1993-10-29
ES529360A0 (es) 1984-10-01
ES8403522A1 (es) 1984-03-16
US4820638A (en) 1989-04-11
FI831818A0 (fi) 1983-05-23
DE3220116A1 (de) 1983-12-01
DD211359A5 (de) 1984-07-11
MX9202815A (es) 1992-06-30
GR79236B (enrdf_load_stackoverflow) 1984-10-22
NO831903L (no) 1983-11-29
HU196452B (en) 1988-11-28
UA8037A1 (uk) 1995-12-26
AU565479B2 (en) 1987-09-17
SG38692G (en) 1992-09-04
JPS5925689A (ja) 1984-02-09
FI82072B (fi) 1990-09-28
JPH0774238B2 (ja) 1995-08-09
DD211359C4 (de) 1986-09-24

Similar Documents

Publication Publication Date Title
KR920006349B1 (ko) 미생물을 이용한 α- 및 β-인터페론의 제조방법
US5541312A (en) Production of interferon
US7635466B1 (en) DNA sequences, recombinant DNA molecules and processes for producing human fibroblast interferon-like polypeptides
US4530901A (en) Recombinant DNA molecules and their use in producing human interferon-like polypeptides
EP0032134B2 (en) Dna sequences, recombinant dna molecules and processes for producing human interferon-alpha like polypeptides
JP2662520B2 (ja) 大きな構造遺伝子の製造および発現
DK174927B1 (da) DNA, der koder for human faktor VIII:C, vektor omfattende denne DNA, transformeret vært omfattende denne DNA, og fremgangsmåde til fremstilling af human faktor VIII:C
US5089400A (en) Polypeptides and process for the production thereof
HU193512B (en) Process for preparing hybride interferones from human erythrocytes
IE50378B1 (en) A dna transfer vector for human pre-growth hormone,a microorganism transformed thereby,and a method of cloning therefor
JPS6156199A (ja) 新規ヒトインタ−フエロンα類
EP0133321B1 (en) Dna gene, process for production thereof and plasmid containing the same
US6835557B1 (en) DNA sequences, recombinant DNA molecules and processes for producing human interferon-like polypeptides
JPS60126299A (ja) 新規インターフェロンγとその製造方法
JPS61149089A (ja) Ｄｎａ塩基配列、ポリペプチド分泌発現ベクター及び形質転換微生物
KR890001828B1 (ko) 인터페론-α형의 폴리펩티드의 제조방법
CN119876266A (zh) 重组猪巨噬细胞集落刺激因子的真核表达质粒及其构建方法和应用
JPH0129557B2 (enrdf_load_stackoverflow)

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E601 Decision to refuse application
E902 Notification of reason for refusal
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 19970723

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 19980804

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 19980804

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000